Chris W Hollen1, M Mateo Paz Soldán1, John R Rinker1, Rebecca I Spain1. 1. is Multiple Sclerosis Fellow and is a Neurologist and the Associate Director of Clinical Affairs for the MSCoE-West, both at the VA Portland Health Care System in Oregon. is a Neurologist and the Clinical Director of the MSCoE-West Regional Program at the VA Salt Lake City Health Care System in Utah. is a Neurologist and the Clinic Director of the MS Clinic at the Birmingham VA Medical Center in Alabama.
Abstract
INTRODUCTION: Multiple sclerosis (MS) affects more than a million people in the US. A considerable portion of these patients either begin with primary progressive disease or eventually transition to secondary progressive MS. A progressive disease course is the most critical factor affecting disability accumulation. The relatively recent development of treatments for relapsing multiple sclerosis has had a profound impact on the disease course for many with MS. Unfortunately, therapies for progressive MS have not had the same degree of advancement in general. New insights into the pathophysiology of progressive MS may lead to new treatments. OBSERVATIONS: In this review, we identify some of the significant challenges encountered in the development of therapies for progressive MS, assess the evidence for use of currently approved therapies for patients with progressive MS, identify some of the current therapies in development from progressive MS, and consider the role for discontinuing therapy in certain patients. CONCLUSIONS: Developing effective disease modifying therapies that slow or stop the gradual accumulation of neurologic disability in progressive MS represents a critical unmet need. As the understanding of the inflammatory and neurodegenerative aspects of MS are better elucidated there may be opportunity for advancement in the treatment of progressive MS.
INTRODUCTION: Multiple sclerosis (MS) affects more than a million people in the US. A considerable portion of these patients either begin with primary progressive disease or eventually transition to secondary progressive MS. A progressive disease course is the most critical factor affecting disability accumulation. The relatively recent development of treatments for relapsing multiple sclerosis has had a profound impact on the disease course for many with MS. Unfortunately, therapies for progressive MS have not had the same degree of advancement in general. New insights into the pathophysiology of progressive MS may lead to new treatments. OBSERVATIONS: In this review, we identify some of the significant challenges encountered in the development of therapies for progressive MS, assess the evidence for use of currently approved therapies for patients with progressive MS, identify some of the current therapies in development from progressive MS, and consider the role for discontinuing therapy in certain patients. CONCLUSIONS: Developing effective disease modifying therapies that slow or stop the gradual accumulation of neurologic disability in progressive MS represents a critical unmet need. As the understanding of the inflammatory and neurodegenerative aspects of MS are better elucidated there may be opportunity for advancement in the treatment of progressive MS.
Authors: Marisa P McGinley; Philip A Cola; Robert J Fox; Jeffrey A Cohen; John J Corboy; Deborah Miller Journal: Mult Scler Date: 2019-08-01 Impact factor: 6.312
Authors: Raju Kapoor; Julian Furby; Thomas Hayton; Kenneth J Smith; Daniel R Altmann; Robert Brenner; Jeremy Chataway; Richard A C Hughes; David H Miller Journal: Lancet Neurol Date: 2010-06-08 Impact factor: 44.182
Authors: Robert J Fox; Christopher S Coffey; Robin Conwit; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robert T Naismith; Akshata Ashokkumar; Janel Barnes; Dixie Ecklund; Elizabeth Klingner; Maxine Koepp; Jeffrey D Long; Sneha Natarajan; Brenda Thornell; Jon Yankey; Robert A Bermel; Josef P Debbins; Xuemei Huang; Patricia Jagodnik; Mark J Lowe; Kunio Nakamura; Sridar Narayanan; Ken E Sakaie; Bhaskar Thoomukuntla; Xiaopeng Zhou; Stephen Krieger; Enrique Alvarez; Michelle Apperson; Khurram Bashir; Bruce A Cohen; Patricia K Coyle; Silvia Delgado; L Dana Dewitt; Angela Flores; Barbara S Giesser; Myla D Goldman; Burk Jubelt; Neil Lava; Sharon G Lynch; Harold Moses; Daniel Ontaneda; Jai S Perumal; Michael Racke; Pavle Repovic; Claire S Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Guttman; Vijayshree Yadav; Aram Zabeti Journal: N Engl J Med Date: 2018-08-30 Impact factor: 91.245
Authors: Meredith D Hartley; Tania Banerji; Ian J Tagge; Lisa L Kirkemo; Priya Chaudhary; Evan Calkins; Danielle Galipeau; Mitra D Shokat; Margaret J DeBell; Shelby Van Leuven; Hannah Miller; Gail Marracci; Edvinas Pocius; Tapasree Banerji; Skylar J Ferrara; J Matthew Meinig; Ben Emery; Dennis Bourdette; Thomas S Scanlan Journal: JCI Insight Date: 2019-04-18
Authors: Raju Kapoor; Pei-Ran Ho; Nolan Campbell; Ih Chang; Aaron Deykin; Fiona Forrestal; Nisha Lucas; Bei Yu; Douglas L Arnold; Mark S Freedman; Myla D Goldman; Hans-Peter Hartung; Eva Kubala Havrdová; Douglas Jeffery; Aaron Miller; Finn Sellebjerg; Diego Cadavid; Dan Mikol; Deborah Steiner Journal: Lancet Neurol Date: 2018-03-12 Impact factor: 44.182
Authors: Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers Journal: Lancet Date: 2002 Dec 21-28 Impact factor: 79.321
Authors: Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman Journal: Neurology Date: 2014-05-28 Impact factor: 9.910